Astria Therapeutics (ATXS) to Release Earnings on Monday

Key Points

• Astria Therapeutics is set to release its Q2 2025 earnings on August 11th, with analysts expecting a loss of ($0.61) per share.
• The company's stock is currently priced at $6.61, and the average price target among analysts is $29.00, indicating positive sentiment towards future performance.
• Institutional investors hold approximately 98.98% of Astria Therapeutics' shares, with Jane Street Group LLC recently increasing its stake by 317.3%.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) will likely be posting its Q2 2025 quarterly earnings results before the market opens on Monday, August 11th. Analysts expect Astria Therapeutics to post earnings of ($0.61) per share for the quarter.

Astria Therapeutics (NASDAQ:ATXS - Get Free Report) last announced its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.10). On average, analysts expect Astria Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Astria Therapeutics Price Performance

Shares of ATXS traded up $0.05 during mid-day trading on Monday, hitting $6.61. The company's stock had a trading volume of 17,463 shares, compared to its average volume of 363,646. The firm has a 50-day moving average price of $5.84 and a 200 day moving average price of $5.79. The stock has a market capitalization of $373.00 million, a price-to-earnings ratio of -3.53 and a beta of 0.48. Astria Therapeutics has a fifty-two week low of $3.56 and a fifty-two week high of $12.92.

Wall Street Analyst Weigh In

Several research analysts have commented on ATXS shares. Cantor Fitzgerald reiterated an "overweight" rating and issued a $47.00 target price on shares of Astria Therapeutics in a report on Wednesday, May 14th. HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a report on Friday, June 13th. Five research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Astria Therapeutics has an average rating of "Buy" and an average target price of $29.00.

Institutional Trading of Astria Therapeutics

A hedge fund recently raised its stake in Astria Therapeutics stock. Jane Street Group LLC increased its stake in shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Free Report) by 317.3% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 108,898 shares of the biotechnology company's stock after purchasing an additional 82,805 shares during the quarter. Jane Street Group LLC owned approximately 0.19% of Astria Therapeutics worth $582,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 98.98% of the company's stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.